What does Chordia Therapeutics Inc. do?
Chordia Therapeutics Inc., a biotech company, engages in research and development of anti-cancer drugs that targets RNA deregulation stress in Japan. It develops CLK CTX-712, a CLK inhibitor, which is Phase 1 clinical trial for the treatment of relapsed or refractory malignant cancers.; CTX-177, a small-molecule…
What is Chordia Therapeutics Inc.'s P/E and P/B ratio?
Chordia Therapeutics Inc. has a P/E ratio of -2.5 and a P/B ratio of 1.61.
What is Chordia Therapeutics Inc.'s debt-to-equity ratio?
Chordia Therapeutics Inc. has a debt-to-equity ratio of 0.00.
How much does Chordia Therapeutics Inc. owe compared with what it owns?
Chordia Therapeutics Inc. owes ¥0.10 for every ¥1 it owns (balance sheet May 2026), which is low.
What is Chordia Therapeutics Inc.'s Positivity rank?
Chordia Therapeutics Inc. is ranked #3,968 of 10,750 companies globally and #1,914 of 3,683 in Japan on PositoAI, with a Positivity Score of 22,173.
Does Chordia Therapeutics Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?
Red flags (PosiRed) are not checked yet for companies in this market on PositoAI, so no result is shown for Chordia Therapeutics Inc..
Where can I read the latest news about Chordia Therapeutics Inc.?
Recent headlines about Chordia Therapeutics Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.
Does Chordia Therapeutics Inc. have a PositoAI PosiShot or QR code?
Yes. A dated PosiShot of Chordia Therapeutics Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.